Presentation is loading. Please wait.

Presentation is loading. Please wait.

Treatment of Acute Graft-versus-Host Disease in Childhood with Extracorporeal Photochemotherapy/Photopheresis: The Padova Experience  Elisabetta Calore,

Published byVittorio Giusti Modified over 6 years ago

Similar presentations

Presentation on theme: "Treatment of Acute Graft-versus-Host Disease in Childhood with Extracorporeal Photochemotherapy/Photopheresis: The Padova Experience  Elisabetta Calore,"— Presentation transcript:

1 Treatment of Acute Graft-versus-Host Disease in Childhood with Extracorporeal Photochemotherapy/Photopheresis: The Padova Experience  Elisabetta Calore, Piero Marson, Marta Pillon, Manuela Tumino, Tiziana Tison, Chiara Mainardi, Giustina De Silvestro, Sara Rossin, Genny Franceschetto, Elisa Carraro, Matilde Pescarin, Stefania Varotto, Roberta Destro, Maria Vittoria Gazzola, Giuseppe Basso, Chiara Messina  Biology of Blood and Marrow Transplantation  Volume 21, Issue 11, Pages (November 2015) DOI: /j.bbmt Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Algorithm for aGVHD treatment used in our center.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 (A) TRM for all patients. (B) TRM for responders and NR to ECP. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 (A) Five-year OS for all patients treated with ECP. (B) Five-year OS for responders and NR to ECP. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

5 Figure 4 (A) Overall 5-PFS of primary disease. (B) Five-year PFS of primary disease according to response to ECP. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

6 Figure 5 (A) Overall 5-year TTP of primary disease. (B) Five-year TTP of primary disease according to response to ECP. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

7 Figure 6 (A) Overall cumulative incidence of relapse of primary disease. (B) Cumulative incidence of relapse of primary disease for responders and NR to ECP. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Treatment of Acute Graft-versus-Host Disease in Childhood with Extracorporeal Photochemotherapy/Photopheresis: The Padova Experience  Elisabetta Calore,"

Similar presentations

Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation.

Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation.
Systematic Review of Controlled Clinical Trials on the Use of Ursodeoxycholic Acid for the Prevention of Hepatic Veno-occlusive Disease in Hematopoietic.

Systematic Review of Controlled Clinical Trials on the Use of Ursodeoxycholic Acid for the Prevention of Hepatic Veno-occlusive Disease in Hematopoietic.
Stephanie J. Lee, Loretta A. Williams 

Stephanie J. Lee, Loretta A. Williams 
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
How to Treat MDS without Stem Cell Transplantation

How to Treat MDS without Stem Cell Transplantation
Early Hyperglycemia after Initiation of Glucocorticoid Therapy Predicts Adverse Outcome in Patients with Acute Graft-versus-Host Disease  Melanie N. Stauber,

Early Hyperglycemia after Initiation of Glucocorticoid Therapy Predicts Adverse Outcome in Patients with Acute Graft-versus-Host Disease  Melanie N. Stauber,
Tumor Necrosis Factor-α Gene Polymorphisms Are Associated with Severity of Acute Graft-Versus-Host Disease Following Matched Unrelated Donor Bone Marrow.

Tumor Necrosis Factor-α Gene Polymorphisms Are Associated with Severity of Acute Graft-Versus-Host Disease Following Matched Unrelated Donor Bone Marrow.
Incidence and Prognostic Value of Eosinophilia in Chronic Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation  Imran Ahmad,

Incidence and Prognostic Value of Eosinophilia in Chronic Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation  Imran Ahmad,
Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health.

Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health.
Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations  Yachiyo.

Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations  Yachiyo.
Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI  Alix O’Meara, Jörg Halter, Dominik.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI  Alix O’Meara, Jörg Halter, Dominik.
KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched.

KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched.
Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease
Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab  Marc Schnitzler, Jens Hasskarl,

Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab  Marc Schnitzler, Jens Hasskarl,
Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation 

Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation 
Daniela Ion, Kristen Stevenson, Sook-Bin Woo, Vincent T

Daniela Ion, Kristen Stevenson, Sook-Bin Woo, Vincent T
Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation  Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,

Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation  Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Oral Manifestations Compatible with Chronic Graft-versus-Host Disease in Patients with Fanconi Anemia  Laura Grein Cavalcanti, Renata L. Fuentes Araújo,

Oral Manifestations Compatible with Chronic Graft-versus-Host Disease in Patients with Fanconi Anemia  Laura Grein Cavalcanti, Renata L. Fuentes Araújo,
Sabina Kersting, Leo F. Verdonck 

Sabina Kersting, Leo F. Verdonck 

Similar presentations

Ads by Google